If this is bought out, it will be for no less than $10/share (unless FDA denies us the label expansion for IBS-C indication, which I seriously doubt will happen).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.